Short answer
MIMEDX GROUP, INC. (MDXG) filed an 8-K current report with the SEC on July 29, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item EX-99.3 (Exhibit EX-99.3), Item EX-99.2 (Exhibit EX-99.2), Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure). MiMedx announced second-quarter 2026 financial results on July 29, 2026.
MIMEDX GROUP, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- MiMedx announced second-quarter 2026 financial results on July 29, 2026
- Detailed results, management commentary, and investor-relevant metrics are contained in Exhibit 99.1 earnings press release
Item 7.01 · Regulation FD Disclosure
- Earnings call scheduled July 29, 2026 at 4:30 PM EDT covering first-quarter 2026 financial and operating results
- Exhibit 99.2 contains slides supporting management’s earnings discussion
- Updated investor presentation furnished as Exhibit 99.3, potentially relevant to revised strategy and outlook男人天堂
Item EX-99.1 · Exhibit EX-99.1
- Q2 net sales $64.4M, down 35% year over year, driven by Wound sales falling 61% to $25.1M
- Surgical sales rose 15% to $39.3M, providing the principal growth engine amid reimbursement pressure
- Gross margin fell to 69.0% from 81.1%, while net loss reached $14.8M and Adjusted EBITDA was negative $8.1M
- Cash declined to $135.8M, with first-half operating cash flow negative $8.1M and free cash flow negative $9.3M
- Sanara acquisition valued at approximately $350M, funded through cash, stock, and a committed $300M term loan, adding substantial leverage and execution risk
Item EX-99.2 · Exhibit EX-99.2
- Sanara acquisition: $350MM enterprise value at $35/share, a 46% premium, expanding MIMEDX’s Surgical footprint
- Financing: $300MM senior secured term loan, six-year maturity at SOFR +6.25%, plus cash and 4.4MM MIMEDX shares
- First full post-close year: combined revenue well above $400MM, over $20MM run-rate synergies, adjusted EBITDA margin above 20%
- Q2 revenue $64MM, up 9% sequentially, with Surgical revenue $39MM, up 15% year over year
- Q2 GAAP net loss $14.8MM and adjusted EBITDA loss $8.1MM, despite approximately $40MM annualized cost savings targeted
Item EX-99.3 · Exhibit EX-99.3
- Sanara acquisition accelerates MIMEDX’s surgical expansion, adding $103MM 2025 revenue and $17MM Adjusted EBITDA
- Purchase price $35 per Sanara share, comprising $33 cash and 0.4735 MIMEDX shares, a 46% premium
- $300 million six-year senior secured term loan at SOFR + 6.25%, with existing credit agreement repayment
- First full year post-close targets combined revenue above $400 million, over $20 million run-rate synergies, and Adjusted EBITDA margin above 20%
- Q2 2026 sales $64MM, but GAAP net loss $15MM and Adjusted EBITDA loss $8MM, highlighting near-term execution and integration risk
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other MIMEDX GROUP, INC. 8-K filings
Get the next MDXG 8-K as it lands
Follow MDXG for push alerts, or ask the research agent what this filing means.